Pulmonary hypertension (PH) results from constriction and remodeling of pulmonary vessels. 
Introduction
Pulmonary hypertension (PH) occurs either as a complication of various abnormal conditions or as a primary disease for which no underlying cause can be found (1) . Persistent vasoconstriction and structural remodeling of the pulmonary vessels are cardinal features of PH (2) but remain largely unexplained. Serotonin (5-hydroxytryptamine, 5-HT) has been suggested to play a major role in the pathogenesis of PH (3) . Vasoconstriction occurs when 5-HT binds to 5-HT 2 and 5-HT 1B/1D receptors expressed by pulmonary smooth muscle cells (4, 5) . In addition, once internalized by a high-affinity selective transporter, 5-HT exerts potent mitogenic and comitogenic effects on pulmonary artery smooth muscle cells (PA-SMCs) (6-8). The 5-HT transporter (5-HTT) is abundantly expressed in the lung (9) and is the target of appetite suppressant drugs reported to increase the risk of primary PH (10, 11). In recent studies of lung tissues and pulmonary arteries from patients undergoing lung transplantation to treat primary PH, we found increased expression of 5-HTT and marked enhancement of the proliferative growth response of cultured PA-SMCs to 5-HT but not to other growth factors (12). Additional data suggested that the increased expression of 5-HTT in these patients was related to polymorphism of the 5-HTT gene promoter (12). A role for 5-HTT in experimental hypoxic pulmonary hypertension has also been clearly established (13) . Therefore, 5-HT, most notably through its specific transporter, appears to be a key player in the pathogenesis of various types of human and experimental PH.
Drugs such as fluoxetine and paroxetine competitively inhibit 5-HTT (14) and, therefore, abolish the in vitro proliferative response of PA-SMCs to 5-HT and also, to a large extent, to serum (8). However, their effects on the development of PH have not been investigated. We reasoned that antidepressant drugs capable of inhibiting 5-HTT may inhibit PA-SMC proliferation and prevent structural remodeling of blood vessels during PH development, not only in vitro, but 3 also in vivo. Hypoxic PH results from both constriction and remodeling of the pulmonary vessels and, consequently, offers the opportunity to compare the effects of 5-HTT inhibitors with those of 5-HT receptor antagonists. Selective effects would be expected, with 5-HTT inhibitors selectively blocking PA-SMC proliferation and 5-HT receptor antagonists selectively reducing 5-HT−induced pulmonary vasoconstriction. In the present study, we investigated the respective roles of 5-HT receptors and 5-HTT on the development of chronic hypoxic PH in mice. For this purpose, we treated mice with one of the specific 5-HTT inhibitors citalopram and fluoxetine (14) , with the selective 5-HT 1B/1D receptor antagonist GR127935 (15) , or with the 5-HT 2A receptor antagonist ketanserin (16) .
Materials and Methods (words : 1225)

Animal models and experimental design
All experiments were performed using adult male mice (8-week-old C57BL6/J) according to institutional guidelines that comply with national and international regulations.
Hemodynamic response of normoxic mice to acute hypoxia
Mice were anaesthetized with ketamine (6 mg/100 g, i.p.) and xylazine (1 mg/100 g, i.p.).
The trachea was cannulated, and the lungs were ventilated with room air at a tidal volume of 0.2 ml and a rate of 90 breaths per minute. Systemic arterial pressure was determined by catheterization of the carotid artery. A 26-gauge needle was then introduced percutaneously into the right ventricle via the subxyphoid approach. Right ventricular systolic pressure (RVSP) was measured using a Gould P10 EZ pressure transducer connected to pressure modules and a Gould TA 550 recorder. RVSP and heart rate were recorded while the animal was ventilated with room air and then after 5 minutes of ventilation with a hypoxic gas mixture (8% O 2 , 92% N 2 ). The heart rate under these conditions was between 300 and 400 bpm. If the heart rate fell below 300 bpm, measurements were excluded from analysis.
Exposure to chronic hypoxia
Mice were exposed to chronic hypoxia (10% O 2 ) in a ventilated chamber (500-liter volume, Flufrance, Cachan, France), as previously described (13) . To establish the hypoxic environment, the chamber was flushed with a mixture of room air and nitrogen, and the gas was recirculated. The chamber environment was monitored using an oxygen analyzer (Servomex OA150, Crowborough, England). Carbon dioxide was removed by soda lime granules, and excess humidity was prevented by cooling the recirculation circuit. The chamber temperature was maintained at 22-24°C. The chamber was opened every other day for 1 hour to clean the cages and replenish food and water supplies. Normoxic mice were kept in the same room, with the same light-dark cycle.
Assessment of pulmonary hypertension
Mice previously exposed to hypoxia or room air for 2 weeks were anesthetized and ventilated with room air as described above. After incision of the abdomen, a 26-gauge needle connected to a pressure transducer was inserted into the right ventricle, and RVSP was recorded immediately. Blood was then sampled for hematocrit determination. Finally, the animals were deeply anesthetized with sodium pentobarbital (4 mg/100 g, i.p) and exsanguinated, and their thorax was opened to remove the lungs and heart. The right ventricle (RV) was dissected from the left ventricle + septum (LV+S), and these dissected samples were weighed.
The lungs were fixed by intratracheal infusion of 4% aqueous buffered formalin at a pressure of 23 cm H 2 O. The entire specimen was immersed in a bath of the same fixative for one week. A midsagittal slice of the right lung including the apical, azygous, and diaphragmatic lobes was processed for paraffin embedding. Sections (5 µm thick) were cut for light microscopy and stained with hematoxylin-phloxin-saffron and orcein-picroindigo-carmine.
In each mouse, 50-60 intraacinar vessels accompanying either alveolar ducts or alveoli were analyzed by an observer blinded to treatment. Each vessel was categorized as nonmuscularized (no evidence of any vessel wall muscularization), partially muscularized (SMCs identifiable in less than three-fourths of the vessel circumference), or fully muscularized (SMCs in more than three-fourths of the vessel circumference). Muscularization was defined as the presence of typical SMCs stained red with phloxin, each exhibiting an elongated shape and square-ended nucleus and bound by two orcein-stained elastic laminae. The percentage of pulmonary vessels in each muscularization category was determined by dividing the number of vessels in that category by the total number counted in the same experimental group.
Pharmacological treatments
To investigate the effects of 5-HTT inhibition and/or 5-HT receptor blockade on acute hypoxic vasoconstriction, nine groups of mice (6-7 in each group) were studied. Inhibition of 5-HTT was achieved by administering citalopram or fluoxetine (10 mg/kg/day, in distilled water by gavage) in the first two groups. Two other groups were treated with the 5-HT 2A receptor antagonist ketanserin or the 5-HT 1B/1D receptor antagonist GR127935, both in a dosage of 2 mg/kg/day, i.p. Four additional groups were treated with a combination of one 5-HTT inhibitor and one 5-HT receptor antagonist. The last group consisted of control animals that received vehicles. The treatments were given for two days, and acute hypoxic vasoconstriction was measured on the following day 1 hour after the last treatment.
The effect of 5-HTT inhibition and/or 5-HT receptor blockade was assessed in mice exposed to normoxia or to hypoxia during 15 days. Six groups of normoxic mice (6 mice in each group) and six groups of chronically hypoxic mice (10-14 in each group) were treated once a day with citalopram (10 mg/kg/day), fluoxetine (10 mg/kg/day) (17, 18) , ketanserin (2 mg/kg/day) (19) , GR127935 (2 and 10 mg/kg/day) (20, 21) , or vehicle. An additional group was treated with both fluoxetine (10 mg/kg/day) and GR127935 (2 mg/kg/day).
Effect of 5-HT on proliferation of human pulmonary artery smooth muscle cells (PA-SMCs)
The methods used to culture and to characterize human PA-SMCs have been previously described (12). In brief, PA-SMCs were obtained from patients undergoing lung resection for cancer. They were seeded in 24-well plates at a density of 5x10 4 cells/well and allowed to adhere in DMEM supplemented with 15% fetal calf serum (FCS). The cells were then subjected to 48 hours of growth arrest in medium containing only 0.2% FCS before being incubated in DMEM supplemented with 0.2% FCS, 0.6 mM of ascorbic acid, 0.1 mM of iproniazid (a monoamine oxidase inhibitor), and 0.6 µCi/mL of [ 3 H]thymidine, with or without 5-HT (10 -8 to 10 -6 M).
The effect of 5-HT was also examined in the presence of 10 -6 M of fluoxetine, citalopram, GR127935, ketanserin, or the 5-HT 2B/2C receptor antagonist SB206553 (16) . Each of these drugs was added 20 minutes before 5-HT. After incubation for 24 hours, the cells were washed twice with PBS, treated with ice-cold 10% trichloroacetic acid (1 ml/well), and dissolved in 0.1 N NaOH (0.5 ml/well). The incorporated radioactivity was counted and reported as counts per minute (cpm) per well. 
Chemicals
Statistical analyses
All results are expressed as means±SEM.
To compare the effects of pretreatment with 5-HTT inhibitors or 5-HT receptor antagonists on pressure changes caused by acute hypoxia, two-way ANOVA with repeated measurements was performed: significance was tested for pretreatment effect, RVSP under normoxic and hypoxic conditions, and interaction. When interaction was significant, the Mann-Whitney nonparametric test was used to compare the effects of the treatments.
One-way ANOVA was performed to compare hemodynamic values in mice treated with vehicle or active drugs during continuous exposure to chronic hypoxia. When ANOVA indicated significant differences between groups, Scheffe's method was used to compare those groups.
Between-group comparisons of ratios of right ventricle over left ventricle+septum (RV/LV+S) weights and of hematocrits were performed using a similar statistical analysis after arcsine transformation of individual values.
To compare the degree of pulmonary vessel muscularization in the various groups of animals, the vessels were ordinally classified as nonmuscularized, partially muscularized, and fully muscularized (see above). Muscularization was compared at both the alveolar duct and the wall levels, using the nonparametric Kruskal-Wallis test. When a significant difference was observed (P<0.05), multiple pairwise comparisons were performed using Scheffe's method. 
Results
Effects
Effects of 5-HTT inhibitors and 5-HT receptor antagonists on response to acute hypoxia
Exposure to acute hypoxia (10% O 2 ) induced an increase in RVSP in each of the control mice, reaching a maximum at 5 minutes. Two days of pretreatment with a 5-HTT inhibitor, i.e., citalopram or fluoxetine, did not alter baseline RVSP but potentiated its increase in response to acute hypoxia, to 172% and 142% of the pressor response in vehicle-treated controls, respectively (P<0.01 and P<0.05, Fig. 2 ). The 5-HT 2A receptor antagonist ketanserin altered neither the response to acute hypoxia nor its potentiation by citalopram or fluoxetine (Fig. 2) . In contrast, pretreatment with the 5-HT 1B/1D receptor antagonist GR127935 abolished the pressor response to hypoxia, and RVSP in mice given GR127935 plus a 5-HTT inhibitor did not differ from that in control mice treated with vehicle only (Fig.2) .
Effects of chronic treatment with 5-HTT inhibitors or 5-HT receptor antagonists on physiological parameters during normoxia
Treatment with either a 5-HTT inhibitor or a 5-HT receptor antagonist did not alter body weight, heart rate, or systemic arterial pressure. Mean systemic arterial pressure, which was 88±7 mmHg in the control mice, remained unchanged after treatment with fluoxetine (86±5 mmHg), citalopram (87±7 mmHg), GR127935 (85±6 mmHg), or ketanserin (83±4 mmHg). None of these drugs affected RVSP (Fig. 3A) or the RV/LV+S ratio ( Fig 3B) . Muscularization of distal pulmonary arteries, which was less than 5% in the normoxic animals (Fig 4) , was not affected by these drugs.
Effects of 5-HTT inhibitors and 5-HT receptor antagonists on the development of PH
Right ventricular systolic pressure
After 2 weeks of exposure to hypoxia (10% O 2 ) combined with daily administration of citalopram, fluoxetine, GR127935, ketanserin, or vehicle, no differences in body weight, heart rate, or hematocrit were found among the corresponding groups of mice (Table 1) .
Exposure to hypoxia produced a significant increase in RVSP (31.2±0.6 mmHg as compared with 17.5±0.7 mmHg in mice maintained in normoxia, P<0.001, Fig 3A) . Concomitant treatment with citalopram or fluoxetine significantly attenuated this response, whereas RVSP values in mice given ketanserin or GR127935 (2 or 10 mg/kg/day) throughout the hypoxic period did not differ from those found in the hypoxic vehicle-treated animals. Under normoxic conditions, none of these treatments affected RVSP (Fig 3A) .
Right ventricular hypertrophy
At the end of exposure to chronic hypoxia, LV+S weight in the hypoxic mice did not differ from that in the mice maintained under normoxic conditions (Table 1) , whether or not the hypoxic animals were treated with fluoxetine, citalopram, ketanserin, GR127935, or vehicle.
However, exposure to chronic hypoxia was associated with right ventricular hypertrophy as assessed by the RV/LV+S ratio (41.5±1.5% vs. 25.5±1.3% in hypoxic and normoxic vehicletreated mice, respectively, Fig. 3B ). Right ventricular hypertrophy was less marked in the chronically hypoxic mice treated with citalopram or fluoxetine than in those given the vehicle (Fig. 3B) . In contrast, in mice treated with GR127935 (2 or 10 mg/kg/day) or ketanserin, the RV/LV+S ratio did not differ from that measured in the hypoxic vehicle-treated mice. Moreover, combined treatment with GR127935 plus fluoxetine had no additional effect on right ventricular hypertrophy, as compared to fluoxetine alone (data not shown). Under normoxic conditions, none of these treatments affected the RV/LV+S ratio (Fig 3B) .
Pulmonary vascular remodeling
As compared to normoxic mice treated with vehicle, exposure to chronic hypoxia induced muscularization of the distal pulmonary arteries (P<0.001, Fig.4 ). In mice exposed to chronic hypoxia and receiving concomitant treatment with citalopram or fluoxetine, the muscularization of distal pulmonary vessels was markedly attenuated as compared to the control mice exposed to similar hypoxic conditions (P<0.01, Fig. 4 and 5) . In contrast, treatment with GR127935 (2 or 10 mg/kg/day) or ketanserin did not affect muscularization in response to hypoxia. Moreover, combined treatment with GR127935 plus fluoxetine did not further decrease muscularization of distal pulmonary vessels, as compared to fluoxetine alone (data not shown).
Discussion
In this study, antidepressant drugs that selectively inhibit the serotonin transporter protected against the development of hypoxic PH in mice. These drugs inhibited the proliferation of pulmonary vascular SMCs in vitro and impaired hypoxia-induced pulmonary vascular remodeling in vivo. In contrast, serotonin receptor antagonists, which did not affect SMC proliferation, had no effect on pulmonary vascular remodeling. We found that 5-HTT inhibitors potentiated the pulmonary pressure response to hypoxia, whereas some 5-HT receptor antagonists reduced it. This suggests that structural remodeling of pulmonary blood vessels in response to hypoxia can be reduced independently from an effect on pulmonary vascular tone.
Hypoxia is a well-recognized stimulus for pulmonary blood vessel remodeling.
Classically, chronic hypoxic PH is ascribed to vascular remodeling in response to sustained pulmonary vasoconstriction and to the subsequent increase in pulmonary artery pressure, which presumably trigger hypertrophy and proliferation of the vascular SMCs. Another mechanism possibly involved in this effect is a direct influence of hypoxia on the expression of specific genes controlling SMC proliferation (22) . Recent studies showed that mice with targeted disruption of the 5-HTT gene (5-HTT knock-out mice) developed less severe hypoxic pulmonary hypertension than wild-type (WT) controls (13), pointing to 5-HTT as a key effector for pulmonary vascular remodeling in response to hypoxia.
The serotonin transporter can be selectively inhibited by antidepressant drugs such as fluoxetine and citalopram (14) . As previously reported (8), we confirmed here that these 5-HTT inhibitors, but not the 5-HT 2A receptor antagonist ketanserin, the 5-HT 2B/2C receptor antagonist SB 206553, or the 5-HT 1B/1D receptor antagonist GR127935, inhibited the mitogenic effect of 5-HT on human PA-SMCs. In addition, as expected from such an effect, we found that mice exposed to hypoxia and treated with fluoxetine or citalopram developed less severe PH than the vehicle-treated animals. Not only was RVSP lower, but right ventricular hypertrophy and pulmonary vessel muscularization were also considerably less marked in the 5-HTT inhibitortreated mice than in the vehicle-treated controls. These findings indicate that the ability of these antidepressants to diminish PA-SMC proliferation was responsible for the attenuation of PH.
Interestingly, mice treated with either fluoxetine or citalopram showed a potentiated pulmonary pressure response to acute hypoxia, as compared with vehicle-treated controls. In previous studies, we also observed that the pulmonary pressure response to hypoxia was increased in 5-HTT knock-out mice (13) . One possible explanation is that inhibition of These results contrast with a previous study in which knock-out mice unable to express 5-HT 1B receptors (5-HT 1B −/−) developed less severe PH and vascular remodeling than did wildtype controls (21) . The apparent discrepancy between this study and ours is probably related to differences in the severity of PH. In our study, the PH was more severe in the hypoxic control mice, with greater pulmonary vascular remodeling and, probably a smaller relative contribution of pulmonary vasoconstriction, as compared to the study in knock-out mice (21) . Recent work also showed that 5-HT 2B receptors were involved in hypoxia-induced pulmonary hypertension in mice (30) . Again, pulmonary vascular remodeling was far less severe than in the present study, and this difference is a major obstacle to comparisons of the respective importance of 5-HT 2B
receptors versus the 5-HT transporter. It should also be emphasized that the mechanisms by which 5-HT 2B receptors affect the pulmonary vasculature are presently unknown. Indeed, the 5-HT 2B receptors are not involved in serotonin-induced SMC proliferation, as shown in the present study, nor do they play a role in hypoxic pulmonary vasoconstriction, as reported in the paper cited above (30) .
It is noteworthy that 5-HTT is also the target of appetite suppressant drugs reported to increase the risk of primary PH (10). Dexfenfluramine shares with citalopram and fluoxetine an ability to inhibit platelet 5-HT uptake, but also exerts other effects (31) . It triggers the release of serotonin from platelets and has recently been shown to behave like a 5-HTT substrate, as do other anorectic drugs known or suspected to increase the risk of primary PH, such as aminorex, and chlorphentermine (32) . The effects of dexfenfluramine on experimental pulmonary hypertension have varied across studies, with potentiation of pulmonary vascular remodeling in some studies (30) and reduction (33) or no change (34) 
